An Amgen Inc. lung cancer drug, sotorasib, targets an aggressive genetic mutation called KRAS. In the Phase II trial, this drug has shown to provide durable clinical benefit with pretreated non-small cell…
Everything about lung cancer is here.
An Amgen Inc. lung cancer drug, sotorasib, targets an aggressive genetic mutation called KRAS. In the Phase II trial, this drug has shown to provide durable clinical benefit with pretreated non-small cell…